

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# ClouDr Group Limited

## 智雲健康科技集團\*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9955)**

### PROFIT WARNING

References are made to the announcements of ClouDr Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated August 27, 2025 and October 21, 2025 (the “**Announcements**”) in relation to, among the other things, the termination of certain discloseable transactions, the entering into of a new discloseable transaction and impairment related to strategic divestment and one-off specific provision. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcements.

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders (the “**Shareholders**”) and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025 (the “**Reporting Year**”), the Group is expected to record a consolidated net loss ranging between approximately RMB880 million and approximately RMB980 million as compared to a consolidated net loss of approximately RMB491.4 million for the year ended December 31, 2024.

Based on the information currently available, the Board considers that the expected increase in loss was mainly due to the strategic transformation of the Group to restructure its business model to prioritise high-quality and cash-generation growth by focusing on the core AI capabilities. This has resulted in significant impairment losses recognized on disposals of certain subsidiaries and a one-off specific provision related to a business whose counterparty is under major lawsuits or judicial investigations. Due to the strategic divestment from businesses of sales of medical supplies with low profit margin and transformation to focus on AI-driven P2M business with higher operating efficiency, the net cash inflow in operating activities of the Group is expected to range between approximately RMB50 million and approximately RMB80 million for the Reporting Year as compared to a net cash outflow in operating activities of approximately RMB148.4 million for the year ended December 31, 2024.

The information contained in this announcement is only based on the Company's preliminary assessment with reference to the information currently available to the Company and the unaudited consolidated management accounts of the Group for the Reporting Year and is not based on the financial data or other information which has been audited or reviewed by the Company's independent auditor or the audit committee of the Board. The above data may therefore be subject to adjustments. The Group's actual financial results for the Reporting Year may be different from the disclosure made in this announcement. The Board and the management of the Company have been working closely with its independent auditor to finalize the Group's annual results announcement for the Reporting Year, which is expected to be published by the end of March 2026 pursuant to the requirements of the Listing Rules.

**Shareholders and potential investors are advised not to place undue reliance on the information disclosed herein and are advised to exercise caution when dealing in the securities of the Company. Any Shareholder or potential investor who is in doubt is advised to seek advice from professional advisers.**

By order of the Board  
**ClouDr Group Limited**  
**Kuang Ming**

*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, February 16, 2026

*As at the date of this announcement, the Board comprises Mr. Kuang Ming and Ms. Hu Yue as the executive Directors, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.*

*\* for identification purpose only*